

Carla Scaroni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2105823/publications.pdf>

Version: 2024-02-01

210
papers

7,712
citations

57681

46
h-index

84171

75
g-index

227
all docs

227
docs citations

227
times ranked

5412
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, 188-195.	0.6	2
2	Indication to dynamic and invasive testing in Cushing's disease according to different neuroradiological findings. <i>Journal of Endocrinological Investigation</i> , 2022, 45, 629-637.	1.8	15
3	Diagnostic Accuracy of CT Texture Analysis in Adrenal Masses: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 637.	1.8	22
4	Identification of glucocorticoid-related molecular signature by whole blood methylome analysis. <i>European Journal of Endocrinology</i> , 2022, 186, 297-308.	1.9	7
5	The GIP/GIPR axis in medullary thyroid cancer: clinical and molecular findings. <i>Endocrine-Related Cancer</i> , 2022, 29, 273-284.	1.6	9
6	Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. <i>European Journal of Endocrinology</i> , 2022, 186, K17-K24.	1.9	7
7	Incretin Response to Mixed Meal Challenge in Active Cushing's Disease and after Pasireotide Therapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5217.	1.8	1
8	Current clinical practice for thromboprophylaxis management in patients with Cushing's syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). <i>Orphanet Journal of Rare Diseases</i> , 2022, 17, 178.	1.2	8
9	How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing). <i>Pituitary</i> , 2022, 25, 701-704.	1.6	7
10	The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. <i>Antioxidants</i> , 2022, 11, 1090.	2.2	12
11	The Role of Glucocorticoid Receptor in the Pathophysiology of Pituitary Corticotroph Adenomas. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6469.	1.8	2
12	Glucocorticoid excess and COVID-19 disease. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 703-714.	2.6	36
13	Clinical presentation and management of acromegaly in elderly patients. <i>Hormones</i> , 2021, 20, 143-150.	0.9	11
14	What we have to know about corticosteroids use during Sars-Cov-2 infection. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 693-701.	1.8	30
15	The prevalence of secondary neoplasms in acromegalic patients: possible preventive and/or protective role of metformin. <i>International Journal of Clinical Oncology</i> , 2021, 26, 1015-1021.	1.0	3
16	Autoimmune polyendocrine syndrome type 1: an Italian survey on 158 patients. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2493-2510.	1.8	28
17	Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. <i>Pituitary</i> , 2021, 24, 914-921.	1.6	10
18	Frequently asked questions and answers (if any) in patients with adrenal incidentaloma. <i>Journal of Endocrinological Investigation</i> , 2021, 44, 2749-2763.	1.8	14

#	ARTICLE	IF	CITATIONS
19	A multidisciplinary approach to the management of adrenal incidentaloma. Expert Review of Endocrinology and Metabolism, 2021, 16, 201-212.	1.2	15
20	Low-dose short synacthen test with salivary cortisol in patients with suspected central adrenal insufficiency. Endocrine Connections, 2021, 10, 1189-1199.	0.8	4
21	Second-Line Tests in the Diagnosis of Adrenocorticotrophic Hormone-Dependent Hypercortisolism. Annals of Laboratory Medicine, 2021, 41, 521-531.	1.2	15
22	Targeted Metabolomics as a Tool in Discriminating Endocrine From Primary Hypertension. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1111-e1128.	1.8	19
23	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology, 2021, 9, 847-875.	5.5	315
24	A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score. Frontiers in Endocrinology, 2021, 12, 747549.	1.5	13
25	Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study. Lancet Diabetes and Endocrinology, 2021, 9, 813-824.	5.5	34
26	Attenuation Value in Adrenal Incidentalomas: A Longitudinal Study. Frontiers in Endocrinology, 2021, 12, 794197.	1.5	12
27	Perioperative multidisciplinary management of endoscopic transsphenoidal surgery for sellar lesions: practical suggestions from the Padova model. Neurosurgical Review, 2020, 43, 1109-1116.	1.2	12
28	Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clinical Gastroenterology and Hepatology, 2020, 18, 1188-1196.e3.	2.4	39
29	Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e12-e22.	1.8	69
30	Rapid disease progression in patient with mismatch-repair deficiency pituitary ACTH-secreting adenoma treated with checkpoint inhibitor pembrolizumab. Anti-Cancer Drugs, 2020, 31, 199-204.	0.7	40
31	New insights to the potential mechanisms driving coronary flow reserve impairment in Cushing's syndrome: A pilot noninvasive study by transthoracic Doppler echocardiography. Microvascular Research, 2020, 128, 103940.	1.1	7
32	Practical Considerations for the Management of Cushing's Disease and COVID-19: A Case Report. Frontiers in Endocrinology, 2020, 11, 554.	1.5	21
33	Human Corticotropin-Releasing Hormone Tests: 10 Years of Real-Life Experience in Pituitary and Adrenal Disease. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3938-e3949.	1.8	22
34	Prognostic significance of the sum of the diameters of single foci in multifocal papillary thyroid cancer: the concept of new-old tumor burden. Therapeutic Advances in Endocrinology and Metabolism, 2020, 11, 204201882096432.	1.4	3
35	Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS. International Journal of Molecular Sciences, 2020, 21, 9554.	1.8	15
36	Pituitary-adrenal axis and peripheral cortisol metabolism in obese patients. Endocrine, 2020, 69, 386-392.	1.1	12

#	ARTICLE	IF	CITATIONS
37	Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. <i>Pituitary</i> , 2020, 23, 534-542.	1.6	7
38	PTH: Redefining Reference Ranges in a Healthy Population—The Role of Interfering Factors and the Type of Laboratory Assay. <i>International Journal of Endocrinology</i> , 2020, 2020, 1-7.	0.6	5
39	Dexamethasone measurement during low-dose suppression test for suspected hypercortisolism: threshold development with and validation. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1105-1113.	1.8	36
40	The haemostatic system in acromegaly: a single-centre case—control study. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1009-1018.	1.8	2
41	The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2020, 21, 165-183.	2.6	17
42	Cushing's syndrome: Overview of clinical presentation, diagnostic tools and complications. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101380.	2.2	60
43	Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature. <i>Pituitary</i> , 2020, 23, 359-366.	1.6	25
44	COVID-19 infection and glucocorticoids: update from the Italian Society of Endocrinology Expert Opinion on steroid replacement in adrenal insufficiency. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1141-1147.	1.8	103
45	COVID-19 outbreak and steroids administration: are patients treated for Sars-Cov-2 at risk of adrenal insufficiency?. <i>Journal of Endocrinological Investigation</i> , 2020, 43, 1035-1036.	1.8	22
46	Approach to patients with pseudo-Cushing™s states. <i>Endocrine Connections</i> , 2020, 9, R1-R13.	0.8	39
47	The role of 68Ga-DOTA derivatives PET-CT in patients with ectopic ACTH syndrome. <i>Endocrine Connections</i> , 2020, 9, 337-345.	0.8	8
48	Hypertension in Cushing™s Syndrome. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2020, , 127-139.	0.1	1
49	Mitotane Concentrations Influence the Risk of Recurrence in Adrenocortical Carcinoma Patients on Adjuvant Treatment. <i>Journal of Clinical Medicine</i> , 2019, 8, 1850.	1.0	31
50	The Effects of Iodine Supplementation in Pregnancy on Iodine Status, Thyroglobulin Levels and Thyroid Function Parameters: Results from a Randomized Controlled Clinical Trial in a Mild-to-Moderate Iodine Deficiency Area. <i>Nutrients</i> , 2019, 11, 2639.	1.7	32
51	Pitfalls in urinary sodium excretion. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1635-1636.	1.0	3
52	Aldosterone in Gynecology and Its Involvement on the Risk of Hypertension in Pregnancy. <i>Frontiers in Endocrinology</i> , 2019, 10, 575.	1.5	16
53	Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 856-862.	1.8	23
54	The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome. <i>Frontiers in Endocrinology</i> , 2019, 10, 321.	1.5	50

#	ARTICLE	IF	CITATIONS
55	Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients. <i>Endocrine</i> , 2019, 66, 360-369.	1.1	16
56	The medical treatment with pasireotide in Cushing's disease: an Italian multicentre experience based on real-world evidence. <i>Endocrine</i> , 2019, 64, 657-672.	1.1	33
57	Letter to Editor: Reply to R.T. Casey (<i>Semin Oncol.</i> 2018 Jun;45(3):151-155). <i>Seminars in Oncology</i> , 2019, 46, 104-105.	0.8	9
58	Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. <i>Anti-Cancer Drugs</i> , 2019, 30, 533-536.	0.7	7
59	Central adrenal insufficiency: open issues regarding diagnosis and glucocorticoid treatment. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1125-1135.	1.4	24
60	Biological effects and potential mechanisms of action of Pistacia lentiscus Chios mastic extract in Caco-2 cell model. <i>Journal of Functional Foods</i> , 2019, 54, 92-97.	1.6	14
61	Crude extract of <i>Origanum vulgare</i> L. induced cell death and suppressed MAPK and PI3/Akt signaling pathways in SW13 and H295R cell lines. <i>Natural Product Research</i> , 2019, 33, 1646-1649.	1.0	19
62	Different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia. <i>Minerva Endocrinologica</i> , 2019, 44, 205-220.	1.7	4
63	Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study. <i>Endokrynologia Polska</i> , 2019, 70, 305-312.	0.3	10
64	Early recognition of aggressive pituitary adenomas: a single-centre experience. <i>Acta Neurochirurgica</i> , 2018, 160, 49-55.	0.9	32
65	Radiotherapy in acromegaly: Long-term brain parenchymal and vascular magnetic resonance changes. <i>Journal of Neuroradiology</i> , 2018, 45, 323-328.	0.6	7
66	Decrease in salivary cortisol levels after glucocorticoid dose reduction in patients with adrenal insufficiency: A prospective proof-of-concept study. <i>Clinical Endocrinology</i> , 2018, 88, 201-208.	1.2	9
67	Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study. <i>Endocrine</i> , 2018, 61, 118-124.	1.1	16
68	Analysis of characteristics and outcomes by growth hormone treatment duration in adult patients in the Italian cohort of the Hypopituitary Control and Complications Study (HypoCCS). <i>Journal of Endocrinological Investigation</i> , 2018, 41, 1259-1266.	1.8	9
69	Cardiovascular autonomic dysfunction in patients with idiopathic diabetes insipidus. <i>Pituitary</i> , 2018, 21, 50-55.	1.6	4
70	Approach to hyponatremia according to the clinical setting: Consensus statement from the Italian Society of Endocrinology (SIE), Italian Society of Nephrology (SIN), and Italian Association of Medical Oncology (AIOM). <i>Journal of Endocrinological Investigation</i> , 2018, 41, 3-19.	1.8	28
71	A 10-year history of secondary hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1772-1774.	0.3	5
72	Secondary Arterial Hypertension: From Routine Clinical Practice to Evidence in Patients with Adrenal Tumor. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2018, 25, 345-354.	1.0	16

#	ARTICLE	IF	CITATIONS
73	Improved salivary cortisol rhythm with dual-release hydrocortisone. <i>Endocrine Connections</i> , 2018, 7, 965-974.	0.8	24
74	Diabetes Mellitus Secondary to Cushing's Disease. <i>Frontiers in Endocrinology</i> , 2018, 9, 284.	1.5	42
75	Effects of pasireotide treatment on coagulative profile: a prospective study in patients with Cushing's disease. <i>Endocrine</i> , 2018, 62, 207-214.	1.1	14
76	Metyrapone treatment in Cushing's syndrome: a real-life study. <i>Endocrine</i> , 2018, 62, 701-711.	1.1	44
77	Daily salivary cortisol and cortisone rhythm in patients with adrenal incidentaloma. <i>Endocrine</i> , 2018, 59, 510-519.	1.1	32
78	Preoperative treatment with metyrapone in patients with Cushing's syndrome due to adrenal adenoma: a pilot prospective study. <i>Endocrine Connections</i> , 2018, 7, 1227-1235.	0.8	13
79	The Adrenal Glands. <i>Endocrinology</i> , 2018, , 387-421.	0.1	0
80	A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype. <i>Endocrine</i> , 2017, 55, 959-968.	1.1	62
81	First-line screening tests for Cushing's syndrome in patients with adrenal incidentaloma: the role of urinary free cortisol measured by LC-MS/MS. <i>Journal of Endocrinological Investigation</i> , 2017, 40, 753-760.	1.8	30
82	The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp ⁺ somatotropinomas. <i>European Journal of Endocrinology</i> , 2017, 176, 543-553.	1.9	39
83	Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. <i>European Journal of Endocrinology</i> , 2017, 176, 453-461.	1.9	66
84	Glucose Metabolism Abnormalities in Cushing Syndrome: From Molecular Basis to Clinical Management. <i>Endocrine Reviews</i> , 2017, 38, 189-219.	8.9	88
85	Long-term treatment of Cushing's disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial. <i>Endocrine</i> , 2017, 57, 156-165.	1.1	40
86	Diagnostic accuracy of increased urinary cortisol/cortisone ratio to differentiate ACTH-dependent Cushing's syndrome. <i>Clinical Endocrinology</i> , 2017, 87, 500-507.	1.2	19
87	Acromegaly is associated with increased cancer risk: a survey in Italy. <i>Endocrine-Related Cancer</i> , 2017, 24, 495-504.	1.6	61
88	Body Composition is Different After Surgical or Pharmacological Remission of Cushing's Syndrome: A Prospective DXA Study. <i>Hormone and Metabolic Research</i> , 2017, 49, 660-666.	0.7	6
89	Acromegaly Is More Severe in Patients With <i>AHR</i> or <i>AIP</i> Gene Variants Living in Highly Polluted Areas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1872-1879.	1.8	34
90	Analysis of GPR101 and AIP genes mutations in acromegaly: a multicentric study. <i>Endocrine</i> , 2016, 54, 762-767.	1.1	30

#	ARTICLE	IF	CITATIONS
91	Second-line tests in the differential diagnosis of ACTH-dependent Cushing's syndrome. <i>Pituitary</i> , 2016, 19, 488-495.	1.6	52
92	Long-term glucocorticoid effect on bone mineral density in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. <i>European Journal of Endocrinology</i> , 2016, 175, 101-106.	1.9	36
93	The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line. <i>Investigational New Drugs</i> , 2016, 34, 531-540.	1.2	13
94	Investigation of N-cadherin/ β 2-catenin expression in adrenocortical tumors. <i>Tumor Biology</i> , 2016, 37, 13545-13555.	0.8	14
95	Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA p.Leu206Arg Mutation. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 3526-3538.	1.8	65
96	Medical Treatment for Acromegaly does not Increase the Risk of Central Adrenal Insufficiency: A Long-Term Follow-Up Study. <i>Hormone and Metabolic Research</i> , 2016, 48, 514-519.	0.7	6
97	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 85-102.	1.1	9
98	Italian Society for the Study of Diabetes (SID)/Italian Endocrinological Society (SIE) guidelines on the treatment of hyperglycemia in Cushing's syndrome and acromegaly. <i>Journal of Endocrinological Investigation</i> , 2016, 39, 235-255.	1.8	30
99	Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. <i>Journal of Neuro-Oncology</i> , 2016, 126, 519-525.	1.4	105
100	A venous thromboembolism risk assessment model for patients with Cushing's syndrome. <i>Endocrine</i> , 2016, 52, 322-332.	1.1	35
101	The Adrenal Glands. <i>Endocrinology</i> , 2016, , 1-35.	0.1	1
102	Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (Hypo-CCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry. <i>Clinical Endocrinology</i> , 2015, 83, 527-535.	1.2	3
103	Clinical use of pasireotide for Cushing's disease in adults. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 425.	0.9	22
104	Age and the metabolic syndrome affect salivary cortisol rhythm: data from a community sample. <i>Hormones</i> , 2015, 14, 392-8.	0.9	13
105	Therapeutic strategies for Cushing's syndrome: an update. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 45-56.	0.5	9
106	Pathogenesis and clinical impact of relative adrenal insufficiency in hospitalized patients with acute decompensation of cirrhosis. <i>Digestive and Liver Disease</i> , 2015, 47, e7.	0.4	0
107	Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center. <i>Journal of Neuro-Oncology</i> , 2015, 122, 189-196.	1.4	50
108	The role of an acute pasireotide suppression test in predicting response to treatment in patients with Cushing's disease: findings from a pilot study. <i>Endocrine</i> , 2015, 50, 154-161.	1.1	12

#	ARTICLE	IF	CITATIONS
109	The hypertension of Cushing's syndrome. <i>Journal of Hypertension</i> , 2015, 33, 44-60.	0.3	125
110	An analysis of different therapeutic options in patients with Cushing's syndrome due to bilateral macronodular adrenal hyperplasia: a single-centre experience. <i>Clinical Endocrinology</i> , 2015, 82, 808-815.	1.2	62
111	The role of inferior petrosal sinus sampling in ACTH-dependent Cushing's syndrome: review and joint opinion statement by members of the Italian Society for Endocrinology, Italian Society for Neurosurgery, and Italian Society for Neuroradiology. <i>Neurosurgical Focus</i> , 2015, 38, E5.	1.0	68
112	Sleep apnea syndrome in endocrine clinics. <i>Journal of Endocrinological Investigation</i> , 2015, 38, 827-834.	1.8	24
113	Screening Tests for Cushing's Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3856-3861.	1.8	56
114	Conventional and Nuclear Medicine Imaging in Ectopic Cushing's Syndrome: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3231-3244.	1.8	113
115	Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?. <i>Pituitary</i> , 2015, 18, 487-493.	1.6	45
116	A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC. <i>Oncotarget</i> , 2015, 6, 32104-32114.	0.8	23
117	Gonadotropin secreting pituitary adenoma associated with erythrocytosis: case report and literature review. <i>Hormones</i> , 2014, 13, 131-139.	0.9	13
118	Diagnosis and complications of Cushing's disease: gender-related differences. <i>Clinical Endocrinology</i> , 2014, 80, 403-410.	1.2	60
119	Activation of the Dopamine Receptor Type-2 (DRD2) Promoter by 9-Cis Retinoic Acid in a Cellular Model of Cushing's Disease Mediates the Inhibition of Cell Proliferation and ACTH Secretion Without a Complete Corticotroph-to-Melanotroph Transdifferentiation. <i>Endocrinology</i> , 2014, 155, 3538-3549.	1.4	32
120	Cortisol and cortisone ratio in urine: LC-MS/MS method validation and preliminary clinical application. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 213-20.	1.4	22
121	Combination therapy for Cushing's disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?. <i>Pituitary</i> , 2014, 17, 109-117.	1.6	86
122	Thrombin generation in Cushing's Syndrome: do the conventional clotting indices tell the whole truth?. <i>Pituitary</i> , 2014, 17, 68-75.	1.6	22
123	Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?. <i>Osteoporosis International</i> , 2014, 25, 441-446.	1.3	49
124	Intracranial internal carotid artery changes in acromegaly: a quantitative magnetic resonance angiography study. <i>Pituitary</i> , 2014, 17, 414-422.	1.6	20
125	The diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing's syndrome: the use of a LC-MS/MS method in routine clinical practice. <i>European Journal of Endocrinology</i> , 2014, 171, 1-7.	1.9	161
126	AHR Over-Expression in Papillary Thyroid Carcinoma: Clinical and Molecular Assessments in a Series of Italian Acromegalic Patients with a Long-Term Follow-Up. <i>PLoS ONE</i> , 2014, 9, e101560.	1.1	27

#	ARTICLE	IF	CITATIONS
127	Venous thromboembolism in patients with Cushing's syndrome: need of a careful investigation of the prothrombotic risk profile. <i>Pituitary</i> , 2013, 16, 175-181.	1.6	34
128	Herniation of cerebellar tonsils in acromegaly: prevalence, pathogenesis and clinical impact. <i>Pituitary</i> , 2013, 16, 122-130.	1.6	10
129	Predicting late recurrence in surgically treated patients with Cushing's disease. <i>Clinical Endocrinology</i> , 2013, 79, 394-401.	1.2	42
130	Performance of salivary cortisol in the diagnosis of Cushing's syndrome, adrenal incidentaloma, and adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2013, 169, 31-36.	1.9	69
131	A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype. <i>PLoS Genetics</i> , 2013, 9, e1003350.	1.5	125
132	Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. <i>Endocrine-Related Cancer</i> , 2013, 20, 753-766.	1.6	50
133	Assessment of glucocorticoid therapy with salivary cortisol in secondary adrenal insufficiency. <i>European Journal of Endocrinology</i> , 2012, 167, 769-776.	1.9	30
134	Potential Role for Retinoic Acid in Patients with Cushing's Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 3577-3583.	1.8	105
135	Predictors of morbidity and mortality in acromegaly: an Italian survey. <i>European Journal of Endocrinology</i> , 2012, 167, 189-198.	1.9	189
136	Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 60-64.	1.8	16
137	Adrenal lesions in acromegaly: Do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up. <i>Journal of Endocrinological Investigation</i> , 2011, 34, 353-360.	1.8	9
138	Volumetric MRI analysis of hippocampal subregions in Cushing's disease: A model for glucocorticoid neural modulation. <i>European Psychiatry</i> , 2011, 26, 64-67.	0.1	38
139	The Glucose-Dependent Insulinotropic Polypeptide Receptor is Overexpressed Amongst GNAS1 Mutation-Negative Somatotropinomas and Drives Growth Hormone (GH)-Promoter Activity in GH3 Cells. <i>Journal of Neuroendocrinology</i> , 2011, 23, 641-649.	1.2	39
140	New Insight into the Hypercoagulability of Cushing's Syndrome. <i>Neuroendocrinology</i> , 2011, 93, 121-125.	1.2	16
141	Increased Rate of Intracranial Saccular Aneurysms in Acromegaly: An MR Angiography Study and Review of the Literature. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1292-1300.	1.8	56
142	Adrenal nodules in patients with Cushing's disease: prevalence, clinical significance and follow-up. <i>Journal of Endocrinological Investigation</i> , 2011, 34, e204-9.	1.8	10
143	Hypercortisolism and pregnancy upregulate von Willebrand factor through different mechanisms: report on a pregnant patient with Cushing's syndrome. <i>Blood Coagulation and Fibrinolysis</i> , 2010, 21, 476-479.	0.5	1
144	Prevalence of AIP mutations in a large series of sporadic Italian acromegalic patients and evaluation of CDKN1B status in acromegalic patients with multiple endocrine neoplasia. <i>European Journal of Endocrinology</i> , 2010, 163, 369-376.	1.9	53

#	ARTICLE	IF	CITATIONS
145	Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. <i>European Journal of Endocrinology</i> , 2010, 162, 85-90.	1.9	18
146	Coagulopathy in Cushing's Syndrome. <i>Neuroendocrinology</i> , 2010, 92, 55-59.	1.2	52
147	Diagnostic and therapeutic challenge in the management of a patient with ectopic adrenocorticotropin secretion. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 507-508.	1.8	2
148	The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect?. <i>Journal of Endocrinological Investigation</i> , 2010, 33, 800-805.	1.8	43
149	Microsatellite (GT) _n is part of the von Willebrand factor (VWF) promoter region that influences the glucocorticoid-induced increase in VWF in Cushing's syndrome. <i>Thrombosis Research</i> , 2010, 125, e275-e280.	0.8	11
150	Microsatellite (GT) _n repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. <i>Thrombosis and Haemostasis</i> , 2009, 101, 298-304.	1.8	11
151	Microsatellite (GT) _n repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions. <i>Thrombosis and Haemostasis</i> , 2009, 101, 298-304.	1.8	7
152	Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. <i>British Journal of Haematology</i> , 2008, 140, 230-235.	1.2	29
153	The Role of Unilateral Adrenalectomy in ACTH-independent Macronodular Adrenal Hyperplasia (AIMAH). <i>World Journal of Surgery</i> , 2008, 32, 882-889.	0.8	82
154	Adrenal morpho-functional alterations in patients with acromegaly. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 602-606.	1.8	18
155	Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 704-710.	1.8	44
156	Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 731-738.	1.8	10
157	Concomitant therapies (glucocorticoids and sex hormones) in adult patients with growth hormone deficiency. <i>Journal of Endocrinological Investigation</i> , 2008, 31, 61-5.	1.8	7
158	The usefulness of combined biochemical tests in the diagnosis of Cushing's disease with negative pituitary magnetic resonance imaging. <i>European Journal of Endocrinology</i> , 2007, 156, 241-248.	1.9	46
159	Cardiovascular Risk Factors and Ultrasound Evaluation of Intima-Media Thickness at Common Carotids, Carotid Bulbs, and Femoral and Abdominal Aorta Arteries in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 1015-1018.	1.8	109
160	Food-dependent Cushing's syndrome: from molecular characterization to therapeutical results. <i>European Journal of Endocrinology</i> , 2007, 157, 771-778.	1.9	38
161	Treatment of polycystic ovary syndrome with spironolactone plus licorice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 131, 61-67.	0.5	61
162	Peroxisome Proliferator-Activated Receptor γ in the Human Pituitary Gland: Expression and Splicing Pattern in Adenomas Versus Normal Pituitary. <i>Journal of Neuroendocrinology</i> , 2007, 19, 552-559.	1.2	15

#	ARTICLE	IF	CITATIONS
163	Cyclic Cushing's syndrome: an overview. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2007, 51, 1253-1260.	1.3	21
164	Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: Preliminary report. <i>Journal of Endocrinological Investigation</i> , 2006, 29, 516-522.	1.8	21
165	Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease. <i>Clinical Endocrinology</i> , 2006, 64, 219-224.	1.2	80
166	Patients with Cushing's Syndrome Have Increased Intimal Media Thickness at Different Vascular Levels: Comparison with a Population Matched for Similar Cardiovascular Risk Factors. <i>Hormone and Metabolic Research</i> , 2006, 38, 405-410.	0.7	58
167	Effect of Short-term Therapy with Recombinant Human Growth Hormone (GH) on Metabolic Parameters and Preclinical Atherosclerotic Markers in Hypopituitary Patients with Growth Hormone Deficiency. <i>Hormone and Metabolic Research</i> , 2006, 38, 16-21.	0.7	11
168	A meta-iodobenzylguanidine scintigraphic scoring system increases accuracy in the diagnostic management of pheochromocytoma. <i>Endocrine-Related Cancer</i> , 2006, 13, 525-533.	1.6	25
169	Residual Pituitary Function after Brain Injury-Induced Hypopituitarism: A Prospective 12-Month Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6085-6092.	1.8	319
170	The M235T polymorphism of the angiotensinogen gene in women with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2005, 84, 1520-1521.	0.5	7
171	Hypopituitarism induced by traumatic brain injury in the transition phase. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 984-989.	1.8	61
172	Idiopathic primary hyperaldosteronism: Normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 236-240.	1.8	16
173	Spirolactone in the treatment of polycystic ovary syndrome: Effects on clinical features, insulin sensitivity and lipid profile. <i>Journal of Endocrinological Investigation</i> , 2005, 28, 49-53.	1.8	88
174	Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. <i>Clinical Endocrinology</i> , 2004, 61, 320-326.	1.2	330
175	Cyclic Cushing's Syndrome: An Overview. <i>Pituitary</i> , 2004, 7, 203-207.	1.6	33
176	Cost-effective therapy in patients with idiopathic hirsutism. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 297-306.	0.7	2
177	Hypopituitarism and growth hormone deficiency (GHD) after traumatic brain injury (TBI). <i>Growth Hormone and IGF Research</i> , 2004, 14, 114-117.	0.5	46
178	Licorice reduces serum testosterone in healthy women. <i>Steroids</i> , 2004, 69, 763-766.	0.8	84
179	High Prevalence of Thyroid Ultrasonographic Abnormalities in Primary Aldosteronism. <i>Endocrine</i> , 2003, 22, 155-160.	2.2	10
180	Clinical and Genetic Aspects of Pheochromocytoma. <i>Hormone Research in Paediatrics</i> , 2003, 59, 56-61.	0.8	16

#	ARTICLE	IF	CITATIONS
181	Unilateral Adrenal Tumor, Erectile Dysfunction and Infertility in a Patient with 21-Hydroxylase Deficiency: Effects of Glucocorticoid Treatment and Surgery. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2003, 111, 41-43.	0.6	12
182	Growth hormone and insulin-like growth factor I in a Sydney Olympic gold medallist. <i>British Journal of Sports Medicine</i> , 2002, 36, 148-149.	3.1	12
183	Furosemide and 11 β -hydroxysteroid dehydrogenase activity, in man. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2002, 110, 272-276.	0.6	8
184	Retinal abnormalities associated with a mutation of the nucleotide 683 in von Hippel-Lindau disease. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2000, 238, 615-620.	1.0	1
185	Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 520-526.	1.8	203
186	Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 520-526.	1.8	173
187	Incidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 55-62.	1.8	160
188	Incidentally Discovered Adrenal Tumors: Endocrine and Scintigraphic Correlates. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 55-62.	1.8	127
189	Steroids and hypertension. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1991, 40, 35-44.	1.2	17
190	17 β -hydroxylase deficiency in three siblings: short- and long-term studies. <i>Journal of Endocrinological Investigation</i> , 1991, 14, 99-108.	1.8	22
191	Deletion within the CYP17 Gene Together with Insertion of Foreign DNA Is the Cause of Combined Complete 17 β -Hydroxylase/17,20-Lyase Deficiency in an Italian Patient. <i>Molecular Endocrinology</i> , 1991, 5, 2037-2045.	3.7	38
192	New Aspects of Mineralocorticoid Hypertension. <i>Hormone Research</i> , 1990, 34, 175-180.	1.8	12
193	Low-dose ketoconazole treatment in hirsute women. <i>Journal of Endocrinological Investigation</i> , 1990, 13, 35-40.	1.8	16
194	HLA and Hormonal Studies in 5 Patients with Late-Onset 21-Hydroxylase Deficiency Syndrome (21OHDS). <i>Obstetrical and Gynecological Survey</i> , 1987, 42, 249-251.	0.2	0
195	Renin-Angiotensin-Aldosterone System: A Long-Term Follow-Up Study in 17 β -Hydroxylase Deficiency Syndrome (17OHDS). <i>Clinical and Experimental Hypertension</i> , 1986, 8, 773-780.	0.3	9
196	HLA and hormonal studies in 5 patients with late-onset 21-hydroxylase deficiency syndrome (21 OHDS). <i>Journal of Endocrinological Investigation</i> , 1986, 9, 65-70.	1.8	3
197	Pharmacokinetics of oral and rectal flurbiprofen in children. <i>European Journal of Clinical Pharmacology</i> , 1984, 27, 367-369.	0.8	14
198	Circadian Secretion of Acth, Cortisol, and Mineralocorticoids in Cushing's Syndrome. <i>Clinical and Experimental Hypertension</i> , 1982, 4, 1779-1794.	0.3	8

#	ARTICLE	IF	CITATIONS
199	Delta Infection and Liver Disease in Hemophilic Carriers of Hepatitis B Surface Antigen. Journal of Infectious Diseases, 1982, 145, 18-22.	1.9	83
200	Inhibitory effect of somatostatin on the aldosterone response to angiotensin II: in vitro studies. Journal of Endocrinological Investigation, 1982, 5, 173-177.	1.8	21
201	Peripheral and Renal Vein Plasma Renin Activity in Hypertensive Urological Patients. British Journal of Urology, 1982, 54, 348-353.	0.1	8
202	HLA AND HORMONAL DATA FOR IDENTIFICATION OF HETEROZYGOTES IN 11?- AND 17?-HYDROXYLASE DEFICIENCY SYNDROMES. Clinical and Experimental Pharmacology and Physiology, 1982, 9, 265-269.	0.9	1
203	Subpopulations of T lymphocytes in primary biliary cirrhosis. Clinical Immunology and Immunopathology, 1981, 20, 255-260.	2.1	5
204	Effect of Angiotensin II and Converting Enzyme Inhibitor (Captopril) on Blood Pressure, Plasma Renin Activity and Aldosterone in Primary Aldosteronism. Clinical Science, 1981, 61, 289s-293s.	0.0	44
205	HLA genotypes and HLA-linked genetic markers in Italian patients with classical 21-hydroxylase deficiency. Human Genetics, 1981, 58, 331-337.	1.8	16
206	Genetic and Hormonal Characterization of Cryptic 21-Hydroxylase Deficiency*. Journal of Clinical Endocrinology and Metabolism, 1981, 53, 1193-1197.	1.8	77
207	No Linkage between HLA and Congenital Adrenal Hyperplasia Due to 17-Alpha-Hydroxylase Deficiency. New England Journal of Medicine, 1980, 303, 530-530.	13.9	12
208	Cryptic 21-Hydroxylase Deficiency in Families of Patients with Classical Congenital Adrenal Hyperplasia*. Journal of Clinical Endocrinology and Metabolism, 1980, 51, 1316-1324.	1.8	110
209	Effect of a Synthetic Substituted $\hat{\pm}$ 1-18 ACTH on Mineralocorticoid Secretion. Hormone and Metabolic Research, 1980, 12, 464-470.	0.7	3
210	Pasireotide-Induced Shrinkage in GH and ACTH Secreting Pituitary Adenoma: A Systematic Review and Meta-Analysis. Frontiers in Endocrinology, 0, 13, .	1.5	14